08 March 2007 | SPL News
Infection Control Saves Lives and Costs
New York, NY (March 8, 2007) - - “Hospital infections affect two million Americans every year, costing 100,000 lives and adding $30.5 billion to the nation’s healthcare tab,” said Betsy McCaughey, Ph.D., founder and chairman of the Committee to Reduce Infection Deaths (RID). “This issue is especially critical for New York right now,” she said, because infection rates of New York hospitals will be made public beginning in 2008.
Dr. McCaughey, Legionella expert Janet E. Stout, Ph.D., University of Pittsburgh, and Bruce Farber, M.D., Chief of Infectious Diseases at North Shore University Hospital, N.Y., met with New York-area hospital executives and infection control professionals today to discuss the latest medical and economic data on infections acquired in the healthcare setting and provide solutions. The seminar, held at the Hilton in Melville, New York, was sponsored by RID and the North Shore-Long Island Jewish (LIJ) Health System with an educational grant from Pall Corporation.
Maureen and Marie Daly of Brooklyn, who lost their mother, Johanna, to a hospital infection in 2004, lent a personal perspective to the clinical discussion. Johanna Daly was a healthy, active 63-year-old when she entered the hospital for repair of a fractured shoulder. Within a few days of her discharge she had a raging fever and died three months later from a severe infection caused by a combination of deadly bacteria.
Dedicating herself to the cause of reducing hospital infection, Maureen Daly gave up her business and joined RID full-time. “It means everything to me to be able to help prevent this from happening to others,” she said.
Dr. Stout, a Microbiologist at the University of Pittsburgh Department of Civil and Environmental Engineering, educated seminar attendees about a less well-known, but no less deadly, source of infection in healthcare settings. Conveying “Lessons Learned from Legionella,” she took participants on a guided tour of hospital water systems – faucets and showers, ice machines, cooling towers, humidifiers and even decorative fountains, where biofilm, Legionella and other deadly microorganisms thrive.
“If you have it in your water, you’re going to have it in your patients,” she warned. “It’s not even necessary for vulnerable patients to come into direct contact with water,” she said. “They can become infected just by breathing the aerosols, which take the form of steam or mist from hospital showers and sinks.”
While Legionnaires’ disease has been the subject of considerable media attention due to several recent outbreaks across the country, Dr. Stout highlighted other waterborne pathogens – bacteria and fungi – that can be as dangerous to patients, including Pseudomonas aeruginosa, Mycobacterium avium and Aspergillus fumigatus.
Infectious disease specialist and seminar moderator Joseph S. Cervia, M.D., Clinical Professor of Medicine & Pediatrics, Albert Einstein College of Medicine, and Medical Director, Pall Corporation, explained why disinfection is so difficult. “The problem of eradicating waterborne microbes from hospital water systems so that patients are not exposed to them is compounded by the growing threat posed by amoebae that ‘harbor’ the microbes and protect them from physical and chemical disinfection technologies,” he said. “The microbes survive and multiply inside the amoebae and are released into hospital water systems, where they can become a source of serious infection.”
Infection Control Can Make the Difference
Dr. McCaughey, a leading national figure in infection prevention and former Lt. Governor of New York, illustrated the cost-effectiveness of infection control. Research shows that eliminating infections can result in a 20-to-1 payback for the hospital within the first year alone, with no or minimal capital outlay. “Good infection control can make the difference between profitability and loss for an individual hospital,” she said.
“Hospitals can ill afford outbreaks,” said Dr. Stout, underscoring the financial impact. “A single outbreak of Legionnaires’ disease can cost anywhere from $880,000 to $1,630,000, not to mention the cost to a hospital’s reputation.”
Dr. Stout reviewed state-of-the-art solutions for reducing Legionella and other waterborne microorganisms, noting that no single systemic disinfection technology can completely and permanently eliminate these pathogens from hospital water systems. “Protection for at-risk patients also requires point-of-use filtration technology,” she said.
Experts Share Solutions, Success Stories
Dr. McCaughey focused on cost-effective measures to curb the alarming rise in methicillin-resistant Staphylococcus aureus (MRSA), one of the deadliest germs responsible for hospital infection and one of the hardest to treat. She presented success stories from hospitals in Virginia, Pennsylvania and Iowa that realized significant reductions in infection rates through simple screening programs and rigorous enforcement of staff and equipment hygiene procedures.
There is no more timely an issue than the importance of implementing effective infection controls, according to Dr. McCaughey, because of the larger impact that it can have on emerging threats such as bioterror and bird flu. “In the event of a major outbreak, proper procedures, rigorously followed, can help reduce infection in first responders, healthcare workers and patients,” she said.
“Minimizing the risk of hospital-associated infections (HAIs) is the highest priority of the North Shore-LIJ Health System,” said Dr. Farber. “The epidemiology and virulence of HAIs change over time, so it is imperative that healthcare providers have control strategies in place to stay ahead of the problem.”
Dr. Farber, who advises on infectious disease issues throughout the North Shore-LIJ system, added that many infections are the product of novel therapies that are being used to treat diseases that in the past were not amenable to therapy. The North Shore-LIJ Health System has implemented a number of programs to minimize risks, in addition to a myriad of standard policies and procedures that are already in place to accomplish this goal. These include participation in the nationwide infection awareness and education campaign being led by the Institute for Healthcare Improvement (IHI); a control program for addressing so-called staph or MRSA infections, including the use of high tech screening of high-risk patients; disinfection, notification and isolation techniques to control Clostridium difficile, a bacterium that can cause serious bowel problems; employee education on hand hygiene and disinfection; surgeon-specific infection rate monitoring; and computer tracking of HAIs.
The Committee to Reduce Infection Deaths (www.hospitalinfection.org) is a nonprofit educational organization dedicated to providing hospital administrators, caregivers, insurers, and patients with the information they need to stop hospital infections.
About North Shore-Long Island Jewish (LIJ) Health System The nation's third largest, non-profit, secular healthcare system, the North Shore-Long Island Jewish Health System (www.northshorelij.com) cares for people of all ages throughout Long Island, Queens and Staten Island – a service area encompassing more than five million people. The health system includes 15 hospitals, four long-term care facilities, a medical research institute, four trauma centers, five home health agencies and dozens of out-patient centers. North Shore-LIJ facilities house more than 6,000 beds, and are staffed by over 8,000 physicians, 10,500 nurses and a total workforce of about 37,500 – the largest employer on Long Island and the ninth largest in New York City. In recognition of its efforts to reduce hospital-acquired infections, the North Shore-LIJ Health System was awarded the 2006 Pinnacle Award by the Healthcare Association of New York State (HANYS).
About Pall Corporation
Pall Corporation (NYSE: PLL) is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, municipal and industrial water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2006 were $2.0 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. For more information visit Pall at www.pall.com